Completed PHASE4 INTERVENTIONAL 2-arm NCT00272831

The Use of Cilostazol in Patients With Diabetic Nephropathy

A Randomised, Double-Blind, Placebo-Controlled Study of Cilostazol 100 mg Twice Daily in the Treatment of Diabetic Nephropathy in Hong Kong Chinese

Sponsor: Chinese University of Hong Kong

Conditions Diabetes Complications Diabetes Mellitus, Type 2

Interventions Cilostazol Placebo

Updated 5 times since 2017 Last updated: May 21, 2009 Started: Dec 31, 2005 Primary completion: Dec 31, 2007 Completion: Dec 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00272831, this PHASE4 trial focuses on Diabetes Complications and Diabetes Mellitus, Type 2 and remains completed. Sponsored by Chinese University of Hong Kong, it has been updated 5 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Dec 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chinese University of Hong Kong

Data source: Chinese University of Hong Kong

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.